Ambros Therapeutics Funding: $125M Raised, Series A (2025)
Ambros Therapeutics is based in Irvine, California. It has raised $125M in total funding. Latest round: Series A.
Ambros Therapeutics funding overview
Ambros Therapeutics is based in Irvine, California. Ambros Therapeutics has raised $125M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in December 2025. The round record for Ambros Therapeutics runs through 2025; nothing later has been disclosed. Investors on record include RA Capital Management, Enavate Sciences, Patient Square Capital, Abiogen Pharma, Janus Henderson Investors, Arkin Bio and 3 others. 9 distinct backers are named across the disclosed rounds.
Ambros Therapeutics at a glance
Total raised
$125M
Latest round
Series A
Latest round date
December 2025
Headquarters
Irvine, California
Notable investors
RA Capital Management, Enavate Sciences, Patient Square Capital, Abiogen Pharma, Janus Henderson Investors, Arkin Bio, Balyasny Asset Management, Transhuman Capital
Frequently asked about Ambros Therapeutics funding
How much has Ambros Therapeutics raised?
Ambros Therapeutics has raised $125M in total disclosed funding across the rounds on record.
Who has invested in Ambros Therapeutics?
RA Capital Management, Enavate Sciences, Patient Square Capital, Abiogen Pharma, Janus Henderson Investors, Arkin Bio are named among the investors backing Ambros Therapeutics.
What was the latest Ambros Therapeutics funding round?
The most recent disclosed round is a Series A, announced in December 2025.
Where is Ambros Therapeutics based?
Ambros Therapeutics is based in Irvine, California.
When did Ambros Therapeutics last raise?
The last disclosed Ambros Therapeutics round closed in December 2025 at Series A.
Round data for Ambros Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Irvine and backer lists below.
